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REGULATION OF EPIDERMAL PROLIFERATION AND
DIFFERENTIATION IN PSORIASIS
JOHN J. VOORHEES
Psoriasis is a genetic disease with an en-
vironmental component. The importance of
the genetic versus the environmental corn-
ponent varies considerably from patient to
patient. Nonetheless, a considerable amount of
research indicates that psoriasis is apparently a
multifactorial genetic disease (1). In psoriasis
patients the frequency of HL-A 13 and HL-A
17 cell surface antigens is elevated fourfold (2).
This information does little to suggest fruitful
avenues of research which will lead to a
molecular understanding of the essence of this
disease.
It is necessary to therefore choose an area of
research in psoriasis which is technically
feasible and likely to have pathophysiological
importance. We have chosen the epidermis.
Stimulated epidermal cell proliferation is a
major feature of psoriasis. The disease would
probably not exist as we know it, if the
epidermis were not a major component. The
vascular compartment or dermal signals to the
epidermis may be more "primary" than the
epidermal disorder. However, the epidermis
with difficulty can be sampled and the
specimens obtained for biochemical analysis
are reasonably free of dermal and vascular
contamination. The vessels, dermis and other
potential candidates can not be adequately
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sampled. To obtain sufficient tissue of either
type would require a surgical technique which
would produce serious scarring and the
procured tissue (vessels and dermis) would be
unacceptably heterogenous. From
heterogenous tissue comes uninterpretable
data. It is for these reasons that our research
has focused on epidermal regulation III
psoriasis.
In this type of research sequential biopsies of
psoriatic epidermis are generally not feasible,
The amount of tissue needed for most
biochemical techniques and the numbers of
patients it is necessary to study due to
biological variation make sequential biopsies
almost impossible. Therefore, one can not
usually decide what is primary or secondary.
Until this type of sequential technology is
available, research on psoriasis will not ad-
vance rapidly. However, until then one can
circumvent this serious drawback by studying
those aspects of the molecular pathophysiology
of psoriasis which are hypothetically amenable
to pharmacological modulation. Using this
philosophical approach one is not concerned
about what is primary or secondary, if the
correction of a pathophysiological event
normalizes the lesion. An important corollary
to our research strategy is that in the initiation
and/or maintenance of a lesion, certain, but
not all molecular events, whether they are
primary or secondary, are critical.
We have termed such events "critical
molecular variables" in psoriatic epidermal
pathophysiology. In this approach the key
ingredient is to make the best educated guesses
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as to which of several thousand events are
critical. Today it is my great honor to be here
in Yonago to address the Japanese Der-
matological Association. My lecture will discuss
and explain these "critical variables" which we
have studied. There are four such areas which I
will consider sequentially: 1) the epidermal cell
surface; 2) cyclic nucleotides; 3) arachidonic
acid-prostaglandin cascade; 4) polyamines.
THE CELL SURFACE
The cell surface acts as a switchboard to
receive incoming signals (hormonal and en-
vironmental stimuli) and to coordinate the
cyclic nucleotide and arachidonic acid systems.
The cell surface is composed of the plasma
membranes, specialized external macromole-
cules (glycoproteins and glycolipids), and
structures on the inner face of the membrane to
which the microtubule-microfilament (MT-
MF) system is attached (3).
In psoriatic lesions the cell surface as
visualized by electron microscopy is markedly
reduced in thickness (4). The area of reduced
thickness is external to the plasma unit
membrane and is the putative binding region
of cell surface hormones. Intuitively, it would
seem that if cell surface defects in psoriasis are
sufficiently gross as to be detected by
microscopy, that serious defects in hormone
binding and cell-cell communication may
exist. DNA synthesis in cultured cells can be
regulated by the addition of membranes (5).
Also, cell surface membrane recognition
factors regulate cyclic AMP and cyclic GMP
levels in reaggregating sponge cells (6). Perhaps
in psoriatic lesions the misregulated cyclic
nucleotide systems are secondary to reduced
cell surface hormone binding or reduced
quantities of macromolecular cell surface
recognition factors. However, in cultured cells
cyclic AMP regulates the formation of the cell
surface (7, 8). A delicate balance appears to
exist between the regulation of the cyclic AMP
system by the cell surface and the regulation of
the cell surface by cyclic AMP.
Defective cell surfaces are also associated
with changes in membrane fluidity. The
amount of cholesterol relative to phospholipid
is one determinant of membrane fluidity. As
the cholesterol/phospholipid ratio increases,
membrane fluidity decreases (9). Since the free
cholesterol content of lesional psoriasis is high,
membrane fluidity should be decreased (10).
Changes in membrane-lipid composition of this
kind have been reported to alter the activity of
membrane bound enzymes such as adenylate
cyclase (9). Therefore, an alteration in cell
surface glycolipids and glycoproteins and in
plasma membrane fluidity could have major
influences on the communication of the cell
surface to the nucleus via cyclic nucleotides.
Psoriasis is said to be a multifactorial genetic
disease (1). The frequency of the cell surface
gene products HL-A 13 and HL-A 17 is in-
creased three to four-fold (11). Whether these
HL-A abnormalities are genetic markers or
participants in the pathophysiology of the
disease is unknown. However, the H-2 gene
complex of the mouse is analogous to the HL-A
gene complex in man. In mice the H-2
genotype is one regulator of the liver cyclic
AMP level (12). The increased frequency of
HL-A 13 and HL-A 17 cell surface components
in psoriasis might frustrate normal cell surface
regulation of the cyclic AMP system.
The MT-MF network is associated with the
cell surface and is thought to relay growth
regulatory information from the cell surface to
the nucleus. Microtubules are composed of
tubulin and microfilaments of actin (13).
Wanger and Sundquist (14) have reported an
accumulation of actin in psoriatic lesional
epithelial cells suggesting the possiblity of an
alteration of the MT-MF system as an im-
portant event in the deranged growth control
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of psoriasis. Puck (13) has shown that for a
normal organized array of MT-MF one must
have normal or increased levels of cyclic AMP.
In psoriasis the cyclic AMP function is reduced
and it might be this reduction which alters the
MT-MF array, thus rendering the array more
prominent when viewed by immunofluorescent
antibody techniques.
Clearly the cell surface of involved areas is
abnormal. Whether this abnormality IS
primary or secondary, it is likely to be im-
portant in lesional pathophysiology for reasons
discussed above. The unusual frequency of the
HL-A cell surface phenotype in psoriasis
suggests that the psoriatic cell surface mem-
brane may be a substantial aspect of the
predisposition to the disease. Cell surface
biochemistry and biophysics are at an ad-
vanced state of technology. Unfortunately
many of these methods require large quantities
of relatively undisturbed membranes. The
isolation of epidermal membranes of any
quantity, and sufficiently intact to be useable,
has not yet been achieved.
Perhaps this membrane technology could be
used to compare psoriatic with normal
membranes from blood lymphocytes. From
lymhocytes adequate membrane preparation
can be achieved. The use of lymphocytes may
be successful if the psoriatic genotype is ex-
pressed in the lymphocyte and in the lym-
phocyte membrane specifically. If so, hormone
receptor binding, glycoprotein/glycolipid
profiles, and membrane fluidity could be
studied in normal subjects in comparison with
psoriasis patients. However, it is possible that
psoriasis genes are expressed only or
predominantly in the skin. If so, the psoriatic
skin membrane studies will await a new
technology. As mentioned previously, the cell
surface and cyclic AMP are a functioning unit
with the cell surface serving as a switchboard
for incoming stimuli (injury or hormonal etc.).
We must therefore discuss the cyclic AMP
system in psoriasis at this point.
THE CYCLIC AMP SYSTEM
The characteristic features of involved
psoriatic epidermis are increased basal cell
proliferation (15, 16), increased glycogen
content in the center of the hyperplastic rete
peg (17), and reduced morphological
differentiation in the outer one third of lesional
epidermis (18). In 1971 we proposed that these
abnormalities might be due to a defective cyclic
AMP system (19). Metabolic regulation
mediated by cyclic AMP depends not on cyclic
AMP per se, but on the differentiated state of
the cell in which the regulation occurs. In
various cells and cell layers, cyclic AMP, at
least in many cases, is a promoter of the ex-
pression of differentiated properties (20). Thus
a defective epidermal cyclic AMP system could
be expected to produce one kind of ab-
normality in one epidermal layer (i.e., in-
creased proliferation) and yet a different
abnormality in a higher layer.
This theory was based on several earlier
observations. Bullough and Laurence (21)
showed that epidermal cell division was
inhibited by epinephrine. Johnson and Past an
(22) reported that cyclic AMP elevating agents
stimulated morphological differentiation in
cultured fibroblasts. Sutherland and RaIl (23)
had previously demonstrated that cyclic AMP
was the mediator of beta adrenergic
epinephrine induced phosphorylase activation
and glycogen breakdown. Thus, it seemed that
decreased function of the cyclic AMP system
might result m proliferation, decreased
differentiation and glycogen storage within the
lesion and that stimulation of the cAMP system
might normalize these changes.
This concept was supported by studies
showing a statistically significant 43 percent
decrease in lesional cyclic AMP content in
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comparison with uninvolved or normal
epidermis (24). Subsequently, using a different
assay we demonstrated a lesser but statistically
significant 36% decrease in the cyclic AMP
content of lesional epidermis (25). These
lesion al- cyclic AMP reductions have not been
confirmed by others. Harkonen et al. (26)
reported increased lesional cyclic AMP levels
and Yoshikawa et al. (27) detected no change.
Since quite different psoriatic tissue
preparations have been used by each research
group, it is not surprising that different data
have been generated. Considering the
technical difficulties in procuring biopsies from
psoriatic patients and the large number of
patients already studied, it seems unlikely that
further study of the cyclic AMP level will be
productive.
Also the cyclic AMP level per se is but one
possible defect in the cyclic AMP system. This
system is composed of several sequential steps
from the epidermal cell surface receptor to the
as yet unstudied putative protein substrates in
the epidermis which are phosphorylated by
cyclic AMP dependent protein kinases (28). A
defect in this system or interference with its
function should reduce the extent of cyclic
AMP mediated epidermal protein phosphory-
lation (Fig. 1). Thus a reduced "cyclic AMP
effect" could be produced by interference with
one of the several components of the cyclic
AMP system. This is a tenable postulate since
all evidence to date suggests that the epidermal
cyclic AMP system is similar to that of other
tissues (28).
As yet no study of cyclic AMP dependent
protein phosphorylation in psoriatic epidermis
has been reported. However, the functional
state of the psoriatic epidermal cell surface
receptor-adenylate cyclase complex has been
studied. Yoshikawa et al. (29) have reported
that involved psoriatic epidermis contains less
cyclic AMP than uninvolved epidermis after
both have been stimulated by beta
catacholamine. Also involved areas produce
less cyclic AMP than uninvolved when
stimulated by prostaglandin of the E series
(30). In confirmation of these date Mahrle and
Orfanos (31) have found reduced cyclic AMP
formation III response to isoproterenol
stimulation using cytochemical techniques in
psoriasis. Thus the capacity of involved
psoriatic epidermis to produce cyclic AMP in
response to hormonal signals appears to be
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Fig. 1. Hypothetical Interrelationships of Cyclic AMP, Arachidonic Acid and Polyamines in the
Regulation of Epidermal Proliferation and Differentiation in Psoriasis. Abbrev: ODC, ornithine
decarboxylase; Pu, putrescine; Sp, spermidine; Sm, spermine; AA, arachidonic acid; cAMP,
cyclic adenosine 3',5' monophosphate: CO, cyclooxygenase; PLA., phospholipase As-
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reduced. It is difficult to see how this reduced
cyclic AMP synthetic activity could result in
increased lesional cyclic AMP levels as reported
by Harkonen et al. (26). However, it is com-
patible with either normal or reduced lesional
cyclic AMP levels as shown by Yoshikawa et al.
(27) and Voorhees et al. (24), respectively.
There are several more recent pieces of in-
formation which, although indirect. are
compatible with a defective cyclic AMP system
in psoriasis. Lithium is a known inhibitor of
adenylate cyclase (32). Furthermore, if one
incubates psoriatic epidermis in lithium at a
concentration found in the blood stream of a
lithium controlled manic depressive patient.
cyclic AMP formation In response to
isoproterenol is markedly inhibited by the
lithium (33). Psoriatic patients who develop
manic depressive illness have been reported in
whom as the mania improves. the psoriatic
lesions become resistant to methotrexate and
topical steroids (34) and uninvolved areas
become involved (35). The possible ill-
volvement of inhibited cyclic AMP synthesis in
this response of psoriatic patients to lithium
must be considered.
A beta adrenergic blocking agent, practolol,
formerly available in Europe. and propranolol,
another beta blocker, have been reported to
precipitate several types of rashes, one of which
is psoriasis-like (36). Intracutaneous testing
failed to support the possibility that this
reaction was the result of type I or type IV
hypersensitivity (36). Possibly beta blockers
prevent cutaneous beta catecholamines from
maintaining a normal epidermal cyclic AMP
content. As in the case of lithium, psoriatic
patients taking oral practolol were resistant to
antipsoriatic therapy and new psoriatic lesions
developed.
Subsequently, Wiley and Weinstein (37)
injected propranolol into clinically uninvolved
psoriatic skin and into the skin of normal
subjects. By autoradiography they demon-
strated that propranolol produced a 6-fold
increase in the number of proliferating cells in
psoriatic epidermis. These data might be
explained by a genetically impaired cyclic
AMP generating system in psoriatic skin which
IS further compromised to a' point of
malfunction (i.e .• increased cell proliferation)
by propranolol. In summary. it is interesting
that two structurally different agents (i.e.,
lithium and beta blockers) both inhibit cyclic
AMP formation and both promote the for-
mation of new lesions and render existing
lesions refractory to both systemic and topical
antipsoriasis drugs.
Other molecular observations have been
made in lesional psoriatic epithelium which are
compatible with a malfunctioning cyclic AMP
system. Vassalli et al.(38) demonstrated that
plasminogen activator production in cell
culture is inhibited by compounds which raise
the cellular cyclic AMP level and is inhibited by
glucocorticoids. The plasminogen activator
activity in lesional epithelium is increased (39).
Glucocorticoids are known to markedly im-
prove psoriasis and substances which can
elevate intracellular cyclic AMP content also
improve psoriasis when applied topically (40.
41).
The presence of increased glycogen levels in
psoriatic lesions is perhaps of minimal
metabolic significance. However. its presence is
interesting because when normal or involved
psoriatic epidermis IS incubated with
epinephrine, glycogen breakdown occurs (42).
Thus. epidermal glycogen can be regulated by
cyclic AMP as can glycogen in other cells. The
location of glycogen in the more central areas
of lesional epidermis may indicate that cells in
that location are experiencing a reduced cyclic
AMP signal.
As discussed above, our earliest theory
proposed that cyclic AMP in epidermis might
246 VOORHEES
serve as an antiproliferative compound and a
morphogen (19). This theory has been studied
by several researchers using epidermal cells in
culture. Delescluse et al. (43) demonstrated
that elevated cyclic AMP inhibited the
proliferation of guinea pig epidermal cells in
vitro. Flaxman and Harper (44) later
demonstrated that the proliferation of human
keratinocytes III culture were markedly
inhibited by several compounds which resulted
in cyclic AMP elevation. Delescluse et al. (45)
reported that epidermal cell differentiation was
stimulated in vitro by cyclic AMP additions to
the cultures. This observation was extended by
Chopra (46) who saw that keratohyalin granule
production was stimulated by cyclic AMP
added to human epidermal cells in culture.
If the net cyclic AMP effect is decreased in
psoriatic lesional epithelium, lesions might
improve if stimulated by cyclic AMP.
Posternak et al. (47) injected dibutyryl cyclic
AMP with and without theophylline directly
into psoriatic lesions with modest results. In
China (48) cyclic AMP or dibutyryl cyclic AMP
was administered intramuscularly or in-
travenously to psoriatic patients. Of 69" patients
so treated the authors concluded that this
therapy was effective in 80 percent. Stawiski et
al. (40) applied papaverine topically to
psoriatic lesions in 45 patients and observed a
statistically significant improvement. These
investigators (41) then reported that another
topical cyclic AMP elevating agent known as
Ro 20-1724 produced statistically significant
improvement of psoriasis.
Thus the several molecular and clinical lines
of evidence presented here suggest that the
cyclic AMP system has decreased function in
psoriasis. However, the nature of this
misregulation is not understood and requires
further research. How this research could be
approached experimentally can be visualized in
Figure 1. Cell surface stimuli may not be
properly received by the defective cell surface
(4). Iizuka et al. (49) have provided some
evidence that the cell surface can not properly
receive an incoming beta catecholamine signal
but can normally receive other hormonal
signals which produce elevated cellular cyclic
AMP. Whether this defect is due to generalized
in vivo desensitization (50) or very selective
desensitization (51) is unknown. Thus, the
reduced capacity of lesional epidermis to form
cyclic AMP in the presence of isoproterenol
could be due to prior in vivo receptor desen-
sitization with a genetically normal membrane
beta receptor phenotype. If this is true, the
reduced catecholamine sensitivity should be
temporary and reversible under definable in
vitro conditions. The elevation of lesional cyclic
AMP content according to our theory (19)
should improve the lesion. Therefore, a key
question is whether beta receptor linked cyclic
AMP generation specifically can be related to
pathophysiology. That is, when the lesional
beta receptor is again able to promote the
synthesis of cyclic AMP in vivo, does the lesion
begin to resolve"
Figure 1 also shows how a defect distal to
cyclic AMP formation could produce a func-
tional decrease in the cellular response to cyclic
AMP. The binding of cyclic AMP to the
receptor subunit of cyclic AMP dependent
protein kinase may be impaired. The kinase
could be primarily altered by a genetically
produced amino acid substitution in an area of
the kinase molecule which reduces receptor
binding. Reduced binding, depending on its
extent, could produce reduced function.
Alternatively, the "milieu interieur" (52) of
lesional epidermal cells may not and quite
likely is not normal. That is to say, the
molecular constituents of the intracellular cell
fluid within the epidermal cell plasma
membranes may not be optimal. Enzymic
systems in regulatory biology must have a
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normal microenvironment to properly perform
their catalytic functions. Thus in Figure 1,
cyclic AMP dependent protein kinase and its
specific phosphoprotein substrate(s) may be
normal but the intracellular enzymic micro-
environment may prevent the kinase from
providing normal phosphorylation or the
protein substrate(s) from accepting phos-
phorus. Either functional defect distally could
produce the same "cyclic AMP deficiency state"
as could an actual reduction in the cyclic AMP
level per se, proximally.
It is apparent from examining Figure 1 that
there are several ways by which the necessary
cellular cyclic AMP function can be reduced:
1) reduced ability of the cell surface receptors
to stimulate adenylate cyclase activity thereby
producing reduced cellular cyclic AMP levels;
2) reduced ability of the kinase to carry out the
distal functions of the cyclic AMP which was
formed in response to hormone binding to the
epidermis; 3) reduced ability of the protein
substrate for kinase to act as a phosphate
acceptor. In all these situations, it makes no
difference whether the interference in the cyclic
AMP cascade is primary or secondary. The end
result is the same - reduced epidermal lesional
cyclic AMP function. What does make a
difference is whether the reduced cyclic AMP
signal is biologically important. Throughout
this part of my lecture, I have discussed various
data which suggests that cyclic AMP IS Im-
portant. However, all these data (eg. ,
glycogen, lithium, practolol, in vitro cyclic
AMP effects, topical application of papaverine
and Ro 20-1724, etc.) are indirect and subject
to several interpretations.
Evidence must be developed which directly
proves that cyclic AMP can modulate
epidermal function. If it does, then the
potential participation of cyclic AMP in the
mismodulated psoriatic epidermis is greater.
To this end we have labored over the last three
years on the cultivation of mouse epidermal
cells in vitro. This endeavor has met with
scuccess (53). We are very reproducibly
cultivating primary epidermal cells from
neonatal mice on plastic dishes without the
need for a collagen substrate or 3T3
fibroblasts. Using this system we were quite
surprised but delighted to observe that cyclic
AMP when added to these cells, causes a
several fold increase in their rate of prolifera-
tion. Other hormones which also raised in-
tracellular cyclic AMP caused increased
proliferation. Other studies showed that in
these cells, it was the rise in cyclic AMP that
caused the proliferation and not a rise in cyclic
GMP (54).
We were surprised by these results in that
stimulation rather than inhibition (the ex-
pected result) occurred. However, we were
pleased because any time one speaks of
inhibited proliferation, there is always the
question of whether the inhibition is due to the
known mechanism of action of the inhibitor or
whether the dose response curves were
generated by a fundamentally cytotoxic
substance. It is most unlikely that any cell
system can respond to a cytotoxic agent with
stimulated cell proliferation. It is quite likely
that cell proliferation induced by cyclic AMP
in these cultures is a cyclic AMP specific,
noncytotoxic response. Therefore, in these
cultures it is likely that physiologically oc-
curring cyclic AMP can modulate prolifera-
tion. If one examines the cyclic nucleotide
literature, it is apparent that the tissue response
to elevated cyclic AMP levels is dependent on
the tissue type and the differentiated state of
the tissue. It is therefore possible to advance the
hypothesis that cyclic AMP may stimulate neo-
natal mouse epidermis and inhibit adult
human epidermis either due to different ages,
species or both. To test this hypothesis we are
developing similar cultures of human adult
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epidermis. However, the stimulated prolifera-
tion in neonatal tissue described above makes it
possible to state that cyclic AMP probably does
have an important role in epidermal physiology
and probably in pathology as well. This is an
excellent area for future research and we are
currently continuing along these lines. Since
cyclic GMP has been implicated in psoriatic
pathophysiology, we will discuss cyclic GMP at
this point.
THE CYCLIC GMP SYSTEM
Many investigators agree that cyclic AMP
may modulate in vitro cell proliferation. It ap-
pears that cyclic AMP may be a significant
regulator of proliferation in epidermis as well.
However the role of cyclic GMP in the regula-
tion of cellular growth either in vitro or in vivo
is unclear. Hadden et al. (55) were the first to
discover an association between stimulated
lymphocyte proliferation and elevated levels of
cellular cyclic GMP. Several proliferative cell
systems in which a similar association exists
have been recently reviewed by Goldberg and
Haddox (56). However, several cell prolifera-
tion systems have been described in which the
cyclic GMP content either does not rise or in
fact, falls when proliferation occurs. Perhaps
the best studied situation is that reported by
Nesbitt et al. (57). Rapidly dividing trans-
formed cells in culture were found to have a
low cyclic GMP content and markedly reduced
guanylate cyclase acitivity in comparison with
their nontransformed counterparts. The true
role of cyclic GMP in the regulation of cell
division is unknown.
In psoriasis Voorhees et al. (58) reported an
increased lesional cyclic GMP content. More
recently, Marcelo et al. (59) found elevated
cyclic GMP levels in lesions of a larger group of
psoriatic subjects confirming the earlier report.
Perhaps this elevation of cyclic GMP in
psoriatic lesions is significantly associated with
the increased lesional cell proliferation.
Presently, the elevated cyclic GMP in psoriasis
is an interesting observation, the importance of
which in psoriatic pathophysiology is yet to be
discovered.
From this discussion it seems that misregulat-
ed cyclic AMP action in psoriasis may well be a
fruitful area of future research. Furthermore,
the role of cyclic GMP in lesional patho-
physiology may be more important than can
currently be predicted.
THE ARACHIDONIC ACID-PROSTAGLANDIN
SYSTEM
For this reason we have been interested in
studying the regulation of cyclic nucleotide
(cyclic AMP and cyclic GMP) synthesis in skin.
Agents which raise cyclic AMP in skin are
similar to agents which raise cyclic AMP in
other organs. One of these compounds is
prostaglandin. Prostaglandin is an excellent
candidate in the regulation of cyclic AMP
formation because a locally acting agent is
required. Lesions of psoriasis are in patches
with sharp borders and adjacent normal ap-
pearing skin. If a circulating hormone were
involved in the misregulated cyclic nucleotide
metabolism of psoriasis, the disease would be
generalized rather than located in patches.
Prostaglandins are formed and degraded
locally in tissues and cells and do not circulate
in a hormonally active state (60).
Prostaglandins are synthesized from
arachidonic acid. It is the release of free
arachidonic acid from arachidonic acid
esterified into cell membrane phospholipids
that is the rate limiting reaction in the cascade.
The release of arachidonic acid occurs when
tissues are injured or are hormonally
stimulated (Fig. 2). Released free arachidonic
acid is transformed to a substance known as 12-
L-hydroxy-5, 8, 10, 14-eicosatetraenoic acid
(HETE), cyclic endoperoxides, thromboxane
EPIDERMAL PROLIFERATIO'l AND D1FFFRENTiATION 1'1 PSORL\SIS 249
PHARMACOlOGICAl
BLOCKERS:
XGlUCOCORTICOID
-INDOMETHACI N
LIKE DRUGS
-ETA (TYA)
Pl
!PHOSPHOLIPASE A2
AA
:tCYCLOOXYGENASEpr
l\
PGE2 PGF2a
Fig. 2. Arachidonic Acid-Prostaglandin Cascade in Psoriatic Epidermis. The 26-fold increase in lesional
AA content is 95% inhibited by plastic film occluded glucocorticoid plus cream vehicle. Psoriatic
cyclooxygenase is markedly inhibited by indomethacin whereas both lipoxygenase and
cyclooxygenase are inhibited by ETA. Arachidonic acid in psoriatic epidermis is transformed into
the metabolites seen in this figure. In other tissues different metabolites have bern detected such as
thromboxane and prostacycline. Such metabolites are not detectable in either psoriatic or normal
epidermis. Abbrev: PL, phospholipid; AA, arachidonic acid; PGG. and PGH., the two
prostaglandin cyclic endoperoxides; PGE., prostaglandin E,,; PGF2a prostaglandin F2a ; HPETE,
hydroperoxy-HETE; HETE, 12L-hydroxy-5, 8, 10, 14-eicosatetraenoic acid; ETA (TYA), 5, 8,
11, 14-eicosatetraynoic acid.
and the classical prostaglandins, PGE2 , PGF2a
and PGD 2 (60). These various intermediates all
can modulate the content of cyclic nucleotides
in tissue as reviewed by Voorhees et al. (61).
In an attempt to determine how these
metabolites might regulate cyclic nucleotides
in psoriasis, it was first necessary to identify
these metabolites and their levels in psoriatic
tissue. This was done by Hammarstrom et al.
(62) who reported a 26-fold increase in the
content of free arachidonic acid and an 82-fold
increase in HETE levels in involved versus
uninvolved epidermis. This was a striking
finding since the content of free arachidonic
acid in normal tissues is barely detectable and
that minimal detectable level is usually thought
to have been released by inadvertent tissue
manipulation.
Hamrnarstrom et al. (62) also detected a 40
and 80% increase in the lesionallevels of PGE 2
and PGF2a" respectively. This minimal increase
was unexpected since high arachidonic acid
levels in tissue are usually transformed into
classical prostaglandins. Thus it appears that
in lesional tissue of psoriasis, there is an en-
dogenous inhibition of prostaglandin bio-
synthesis in vivo. In relation to the large
quantity of released arachidonic acid, the
lesion may be said to have a relative prostagl-
andin deficiency. This relative prostaglandin
deficiency may be the result of an endogenous
inhibitor of prostaglandin biosynthesis
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described by Penneys et al. (63). This inhibitor
IS dialyzable but is not susceptible to
ribonuclease, deoxyribonuclease or proteases.
As previously mentioned, the major
disturbance in psoriasis is the large increase in
free arachidonic acid (26-fold) which IS
transformed primarily into HETE. Turner et
al. (64) first reported that HETE was
chemotactic for polymorphonuclear leukocytes
(PMNs). This was confirmed by Goetzl et al.
(65) using human PMNs. Psoriatic lesions have
considerable numbers of PMNs. It is possible
that the high HETE content is an important
factor in the chemoattraction of PMNs into the
lesion. In fact, Penneys et al. (66) injected
arachidonic acid metabolites, one of which was
presumably HETE, intradermally into human
volunteers. They found that this injection
attracted large numbers of PMNs into the
injection site suggesting that the endogenous
HETE content in psoriasis could indeed be one
important chemoattractant.
In psoriasis the release of arachidonic acid
and its transformation into HETE may disturb
cyclic nucleotide metabolism. Wallach and
Past an (67) showed that arachidonic acid per se
stimulated guanylate cyclase activity and thus
is a compound which might promote the ac-
cumulation of cyclic GMP in tissues. Subse-
quently, Hidaka and Asano (68) found that the
hydroperoxy-form of HETE, which is always
formed as arachidonic acid is transformed into
HETE, stimulated guanylate cyclase activity.
Unsaturated fatty acids also inhibit adeny-
late cyclase activity thus preventing the ac-
cumulation of cyclic AMP in tissue. Anderson
and Jaworski (69) showed that arachidonic acid
per se inhibited adenylate cyclase activity. Also
lysolecithin not only is a potent activator of
guanylate cyclase, but it is a potent inhibitor of
adenylate cyclase activity (69, 70). Since
lysolecithin is formed as arachidonic acid is
released in tissues, it is possible that the
lysolecithin content of psoriatic lesions is
elevated. Lysolecithin is also known to be a
potent inhibitor of prostaglandin biosynthesis
at concentrations which are physiologically
plausible (71). Thus the putative elevation in
psoriatic lesionallysolecithin may disturb cyclic
nucleotide synthesis and is also a candidate for
the dialyzable inhibitor of lesional prostagl-
andin biosynthesis described by Penneys et al.
(63).
Although the levels of lesional prostaglandin
E2 and F 2a reported by Hammarstrom et al.
(62) may represent a relative deficiency, the
absolute levels are minimally increased. Since
prostaglandin F2a has been reported to
stimulate the formation of cyclic GMP and
prostaglandin E2 the formation of cyclic AMP,
the elevated lesional levels of these two
prostaglandins in relation to the lesional cyclic
nucleotide content requires comment. In our
hands, prostaglandin F 2a has not been capable
of elevating lesional cyclic GMP and only at
high (I XI0- s to l x10- 5 M) concentrations does
prostaglandin E2 elevate epidermal cyclic
AMP. Also, lesional prostaglandin levels
remain elevated for the life of a lesion. It seems
quite possible that this would possibly lead to in
vivo desensitization of prostaglandin receptors.
When this desensitization phenomenon occurs
cells could be refractory to prostaglandin
induced increases in cyclic nucleotide content
(50). In essence, the cells could perform as
though the increased prostaglandin content did
not exist. Thus the steady state lesional
prostaglandin level may bear little relationship
to the steady state cyclic nucleotide content.
When considering the role of prostaglandins in
the regulation of lesional cyclic nucleotide
content, it is clearly preferable to consider the
role of all the products of arachidonic acid. As
discussed above, the various metabolites of
arachidonic acid are capable of regulating
cyclic nucleotide biosynthesis. In psoriasis
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therefore, it is of interest to know the effect of
arachidonic acid per se, HETE and
hydroperoxy HETE on cyclic nucleotide
synthesis.
Since arachidonic acid levels are markedly
increased in psoriasis, we will briefly consider
its regulation in other tissues for what value
such information may contribute to psoriasis.
The rate limiting enzyme in the synthesis
(release) of free arachidonic acid from
membrane phospholipids IS known as
phospholipase A2 (60). Lapetina et al. (72) and
Minkes et al. (73) have shown that in horse and
human platelets respectively, cyclic AMP
inhibits the release of arachidonic acid
presumably by inhibiting the activity of
phospholipase A2 • Thus In psoriasis by
stimulating the sluggish cyclic AMP system, it
may be possible to correct the abnormally high
release .of arachidonic acid. The cyclic
nucleotide system and the arachidonic acid-
prostaglandin cascade appear to be func-
tionally interdependent. The arachidonic acid
metabolites switch on cyclic AMP formation
which in turn switches off arachidonic acid
release. Whether cyclic AMP does in fact
inhibit arachidonic acid release in psoriatic
lesions is currently under investigation.
THE POLYAMINES
Putrescine, spermidine and spermine are
three substances which are collectively called
polyamines. The rate limiting step in the
conversion of ornithine to putrescine,
putrescine to spermidine, and spermidine to
spermine is the decarboxylation of ornithine by
ornithine decarboxylase (ODe). An elevated
rate of polyamine formation by stimulating
ODe activity appears to be the most constant
correlate of increased cell proliferation (74).
Russell et al. (75) reported that the level of
polyamines is significantly higher in lesional
psoriasis than in uninvolved epidermis and that
ORNITHINE
lODe
PUTRESCINE
lpU-SAMD
SPERMIDINE
lSP-SAMD
SPERMINE
Fig. 3. Polyamine Biosynthesis in Normal and
Psoriatic Human Epidermis. Abbrev: ODe, ornithine
decarboxylase; Pu-SAMD, putrescine-stimulated S-
adenosyl-L-methionine decarboxylase; Sp-SAMD,
spermidine -stimulated S-adenosyl- L -methionine
decarboxylase.
the uninvolved levels are significantly higher
than epidermis from normal volunteers. This
increased polyamine content of uninvolved
epidermis is perhaps a molecular correlate of
the two-fold increase in the labelling index of
uninvolved epidermis versus normal epidermis
(16). Certainly the increased labelling index
and polyamine content of "uninvolved" areas
indicates that there is no such thing as an
uninvolved area at the molecular level.
Although elevated polyamine levels have
been associated with rapid proliferation for
several years (74), it has been only recently that
a possible cause and effect relation between
polyamines and proliferation has been
suggested. Mamont et al. (76) recently showed
that blocking the synthesis of polyamines by an
inhibitor of ODC reduced cell proliferation.
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This inhibition could be overcome by com-
bining polyamines with the ODe inhibitor,
thus bypassing the ODe blokade. Thus the
inhibition of polyamine synthesis by analogs of
ornithine and polyamines per se may offer new
approaches to psoriasis and other proliferative
diseases.
In some cells where cyclic AMP induces
hypertrophy and hyperplasia, cyclic AMP
induces ODe activity and polyamine formation
to accompany the proliferation (77). in lesional
epidermis of psoriasis the studies of Stawiski et
al. (40, 41) indicate that cyclic AMP elevation
probably inhibits cell proliferation. Since
polyamines are already elevated in psoriasis the
cyclic AMP rise could inhibit ODe activity in
lesions of psoriasis. Such an inhibition of ODe
activity has been shown by Insel and Fenno (78)
in lymphoma cells where cyclic AMP also
inhibits cell growth. Whether cyclic AMP
inhibits ODe activity in psoriasis and in this
way participates in the regulation of cell
proliferation in lesions is under current study.
CONCLUSION
Today I have discussed several aspects of the
molecular basis of psoriasis which we consider
to be of unusual importance. I have reviewed
our pragmatic approach to psoriasis research.
This approach has been used because in my
opinion the research tools for studying the
etiology of psoriasis are not available. Until
then, hopefully a dissection of the molecular
systems I have described today will provide
potentially better therapies.
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